Evidence map›Paper›PMID 35696619›Full record

ArticleClinical and translational medicine2022

Altered microRNA expression in severe COVID-19: Potential prognostic and pathophysiological role.

Nathalie Garnier, Kato Pollet, Marie Fourcot, Morgan Caplan, Guillemette Marot, Julien Goutay, Julien Labreuche, Fabrice Soncin, Rabah Boukherroub, Didier Hober and 4 more

Abstract readLetter
In one paragraph

Article in Clinical and translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Nathalie GarnierUniv Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille, France.
Kato PolletUniv Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille, France.
Marie FourcotUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, Lille, France.
Morgan CaplanCHU de Lille, Pôle de réanimation, Lille, France.
Guillemette MarotUniv Lille, CHU Lille, ULR 2694 - METRICS, Lille, France.
Julien GoutayCHU de Lille, Pôle de réanimation, Lille, France.
Julien LabreucheDepartment of Biostatistics, CHU Lille, Lille, France.
Fabrice SoncinCNRS/IIS/Centre Oscar Lambret/Lille University SMMiL-E Project, CNRS Délégation Hauts-de-France, Lille, France.
Rabah BoukherroubUniv Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, Lille, France.
Didier HoberUniv Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille, France.
Lille COVID Research Network (LICORNE)
Sabine SzuneritsUniv Lille, CNRS, Centrale Lille, Univ. Polytechnique Hauts-de-France, UMR 8520 - IEMN, Lille, France.
Julien PoissyCHU de Lille, Pôle de réanimation, Lille, France.
Ilka EngelmannUniv Lille, CHU Lille, Laboratoire de Virologie ULR3610, Lille, France.ORCID 0000-0001-7489-3786

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19MicroRNAsGene Expression Regulation, NeoplasticHumansPrognosisMicroRNAs

Identifiers

PMID35696619
PMCPMC9191908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.